Recently, professor Seung-Woo Cho gave an interview to Dailypharm, as the CEO of CellArtgen.

In this interview, he focused on the future prospects of how lab-developed technologies can be translated into real-world applications. CellArtgen is pursuing a two-track strategy focusing on ORGANOSCREEN - an organoid-based drug evaluation platform- and dECM-based biomaterials. In the short term, the company is commercializing its dECM for use in the cosmetics industry, with plans to expand into the medical device market.

Follow the link for more details

[Link]